Nanoscope Therapeutics Inc.
Jared Stephens is a highly experienced professional who has held leadership roles in companies such as Nanoscope Therapeutics Inc., GE Healthcare, and Bionano Genomics, Inc. Jared has expertise in global strategy, business development, innovation scouting, and managing strategic partnerships. With a PhD in Cell Biology and a Bachelor of Science in Biochemistry, Jared has a strong educational background to support their extensive career in the biotechnology industry.
Nanoscope Therapeutics Inc.
1 followers
Nanoscope Therapeutics is advancing gene therapy using light-sensitive molecules and light-assisted gene delivery for giving sight to the millions of blind individuals suffering from retinal degenerative disease, for which no cure exists. Nanoscope is focused on proprietary ambient light-activated optogenetic therapy to restore vision in people suffering from various inherited retinal degenerative diseases including Retinitis Pigmentosa, Stargardt, and dry AMD. Genetic retinal degenerative diseases cause vision loss as cells of the retina gradually become dysfunctional. Nanoscope’s proprietary gene therapies correct the condition by delivering light-sensitive molecules, called Multi-Characteristic Opsins (MCO), into retinal cells. Update: June, 2021: Nanoscope Therapeutics Announces FDA Approval of IND for Phase 2b clinical trial of Optogenetic Gene Monotherapy to Restore Vision in Patients with Retinitis Pigmentosa